IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway

被引:568
作者
Lee, Dung-Fang
Kuo, Hsu-Ping
Chen, Chun-Te
Hsu, Jung-Mao
Chou, Chao-Kai
Wei, Yongkun
Sun, Hui-Lung
Li, Long-Yuan
Ping, Bo
Huang, Wei-Chien
He, Xianghuo
Hung, Jen-Yu
Lai, Chien-Chen
Ding, Qingqing
Su, Jen-Liang
Yang, Jer-Yen
Sahin, Aysegul A.
Hortobagyi, Gabriel N.
Tsai, Fuu-Jen
Tsai, Chang-Hai
Hung, Mien-Chie
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
[2] Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA
[3] China Med Univ Hosp, Ctr Mol Med, Taichung 404, Taiwan
[4] Asia Univ, Taichung 413, Taiwan
[5] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
关键词
D O I
10.1016/j.cell.2007.05.058
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
TNF alpha has recently emerged as a regulator linking inflammation to cancer pathogenesis, but the detailed cellular and molecular mechanisms underlying this link remain to be elucidated. The tuberous sclerosis 1 (TSC1)/TSC2 tumor suppressor complex serves as a repressor of the mTOR pathway, and disruption of TSC1/TSC2 complex function may contribute to tumorigenesis. Here we show that IKK beta, a major downstream kinase in the TNFa signaling pathway, physically interacts with and phosphorylates TSC1 at Ser487 and Ser511, resulting in suppression of TSC1. The IKK beta mediated TSC1 suppression activates them TOR pathway, enhances angiogenesis, and results in tumor development. We further find that expression of activated IKKb is associated with TSC1 Ser511 phosphorylation and VEGF production in multiple tumor types and correlates with poor clinical outcome of breast cancer patients. Our findings identify a pathway that is critical for inflammation-mediated tumor angiogenesis and may provide a target for clinical intervention in human cancer.
引用
收藏
页码:440 / 455
页数:16
相关论文
共 43 条
[1]   A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression [J].
Anest, V ;
Hanson, JL ;
Cogswell, PC ;
Steinbrecher, KA ;
Strahl, BD ;
Baldwin, AS .
NATURE, 2003, 423 (6940) :659-663
[2]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[3]   The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination [J].
Benvenuto, G ;
Li, SW ;
Brown, SJ ;
Braverman, R ;
Vass, WC ;
Cheadle, JP ;
Halley, DJJ ;
Sampson, JR ;
Wienecke, R ;
DeClue, JE .
ONCOGENE, 2000, 19 (54) :6306-6316
[4]  
BINGLE L, 1995, J PATHOL, V377, P441
[5]   CONTROL OF P70 S6 KINASE BY KINASE-ACTIVITY OF FRAP IN-VIVO [J].
BROWN, EJ ;
BEAL, PA ;
KEITH, CT ;
CHEN, J ;
SHIN, TB ;
SCHREIBER, SL .
NATURE, 1995, 377 (6548) :441-446
[6]   TSC2 regulates VEGF through mTOR-dependent and -independent pathways [J].
Brugarolas, JB ;
Vazquez, F ;
Reddy, A ;
Sellers, WR ;
Kaelin, WG .
CANCER CELL, 2003, 4 (02) :147-158
[7]   Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning [J].
Cai, SL ;
Tee, AR ;
Short, JD ;
Bergeron, JM ;
Kim, J ;
Shen, JJ ;
Guo, RF ;
Johnson, CL ;
Kiguchi, K ;
Walker, CL .
JOURNAL OF CELL BIOLOGY, 2006, 173 (02) :279-289
[8]  
Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO
[9]  
2-2
[10]   The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer [J].
Chang, JY ;
Xia, WY ;
Shao, RP ;
Sorgi, F ;
Hortobagyi, GN ;
Huang, L ;
Hung, MC .
ONCOGENE, 1997, 14 (05) :561-568